一次抗体と二次抗体-抗-エピトープタグ、免疫測定、Cas 9 » MonoRab™ ウサギモノクローナル抗体製品 » MonoRab™ Anti-Pembrolizumab Antibody (90G12), mAb, Rabbit

MonoRab™ Anti-Pembrolizumab Antibody (90G12), mAb, Rabbit

*This product has been discontinued!*
The product is specific for Pembrolizumab. This antibody blocks Pembrolizumab binding with human PD-1 recombinant protein (Z03370, PD‑1 Fc Chimera, Human) in ELISAs.
A01960
Ask us a question
Overview
Specificity The product is specific for Pembrolizumab. This antibody blocks Pembrolizumab binding with human PD-1 recombinant protein (Z03370, PD‑1 Fc Chimera, Human) in ELISAs.
Host Species Rabbit
Immunogen Pembrolizumab
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.01-0.1 µg/ml
Competitive ELISA 10-50 µg/ml

Properties
Form Lyophilized
Storage Buffer lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification Protein A affinity column
Isotype Rabbit IgG
Clonality Monoclonal
Clone ID 90G12
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

Background
Target Background Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
Synonyms Rabbit monoclonal to Keytruda

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.